DK183583A - Fremgangsmaade til fremstilling af benzoazacycloalkyl-spiro-imidazolidiner - Google Patents

Fremgangsmaade til fremstilling af benzoazacycloalkyl-spiro-imidazolidiner Download PDF

Info

Publication number
DK183583A
DK183583A DK183583A DK183583A DK183583A DK 183583 A DK183583 A DK 183583A DK 183583 A DK183583 A DK 183583A DK 183583 A DK183583 A DK 183583A DK 183583 A DK183583 A DK 183583A
Authority
DK
Denmark
Prior art keywords
benzoazacycloalkyl
imidazolidines
spiro
preparing
procedure
Prior art date
Application number
DK183583A
Other languages
English (en)
Other versions
DK183583D0 (da
Inventor
Charles Malen
Jean-Louis Peglion
Jacques Duhault
Michelle Boulanger
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of DK183583D0 publication Critical patent/DK183583D0/da
Publication of DK183583A publication Critical patent/DK183583A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Description

2 2 hvor R' er som R med undtagelse af hydrogen, som kondenseres med et alkalimetalcyanid under tilstedeværelse af ammoniak, hvorefter den fremstillede forbindelse eventuelt debenzyleres og kan acyleres.
Forbindelserne med formlen I er nyttige til behhndling af diabetes, navnlig til bekæmpelse af stigningen i den kapil-lare gennemtrængelighed ved opståen af retinopati og trofiske forstyrrelser, forebyggelse eller behandling af diabetisk neu-ropati i dettes perifere eller indre ytringer og forebyggelse og behandling af katarakt og af diabetisk nefropati.
DK183583A 1982-04-27 1983-04-26 Fremgangsmaade til fremstilling af benzoazacycloalkyl-spiro-imidazolidiner DK183583A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8207203 1982-04-27
FR8207203A FR2525603A1 (fr) 1982-04-27 1982-04-27 Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
DK183583D0 DK183583D0 (da) 1983-04-26
DK183583A true DK183583A (da) 1983-10-28

Family

ID=9273425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK183583A DK183583A (da) 1982-04-27 1983-04-26 Fremgangsmaade til fremstilling af benzoazacycloalkyl-spiro-imidazolidiner

Country Status (22)

Country Link
JP (1) JPS5910584A (da)
KR (1) KR840004428A (da)
AT (1) ATA125383A (da)
AU (1) AU1395383A (da)
BE (1) BE896572A (da)
DD (1) DD209833A5 (da)
DE (1) DE3315106A1 (da)
DK (1) DK183583A (da)
ES (1) ES521895A0 (da)
FR (1) FR2525603A1 (da)
GB (1) GB2133401B (da)
GR (1) GR78481B (da)
IL (1) IL68497A0 (da)
IT (1) IT1167123B (da)
LU (1) LU84770A1 (da)
MA (1) MA19783A1 (da)
NL (1) NL8301476A (da)
NO (1) NO831473L (da)
OA (1) OA07412A (da)
PT (1) PT76595B (da)
SE (1) SE8302347L (da)
ZA (1) ZA832927B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
US7704993B2 (en) 2003-06-17 2010-04-27 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
MXPA05013364A (es) 2003-06-17 2006-03-17 Arena Pharm Inc Procedimiento para preparar 3-benzazepinas.
BRPI0519726B8 (pt) 2004-12-21 2021-05-25 Arena Pharm Inc composto de hemidrato de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina, composição compreendendo o referido composto e seus usos
BRPI0515862A2 (pt) 2004-12-23 2011-10-11 Arena Pharm Inc uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas
JP5199997B2 (ja) 2006-04-03 2013-05-15 アリーナ ファーマシューティカルズ， インコーポレイテッド ８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
JP5404414B2 (ja) 2006-12-05 2014-01-29 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法
US8822727B2 (en) 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
SG188361A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
KR20130138770A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 광학적으로 활성 산을 갖는 로르카세린의 염
US8999970B2 (en) 2010-09-01 2015-04-07 Arena Pharmaceuticals, Inc. Administration of an anti-obesity compound to individuals with renal impairment
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
CA2886875A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209630A (en) * 1976-10-18 1980-06-24 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives

Also Published As

Publication number Publication date
IT8348155A0 (it) 1983-04-26
GB8311508D0 (en) 1983-06-02
JPS5910584A (ja) 1984-01-20
FR2525603A1 (fr) 1983-10-28
NL8301476A (nl) 1983-11-16
DD209833A5 (de) 1984-05-23
MA19783A1 (fr) 1983-12-31
PT76595B (fr) 1986-01-21
LU84770A1 (fr) 1984-11-28
GB2133401B (en) 1985-10-23
ES8405796A1 (es) 1984-06-16
BE896572A (fr) 1983-10-26
ES521895A0 (es) 1984-06-16
ZA832927B (en) 1984-06-27
SE8302347L (sv) 1983-10-28
DK183583D0 (da) 1983-04-26
FR2525603B1 (da) 1984-09-14
AU1395383A (en) 1983-11-03
GR78481B (da) 1984-09-27
IT1167123B (it) 1987-05-13
OA07412A (fr) 1984-11-30
KR840004428A (ko) 1984-10-15
DE3315106A1 (de) 1983-11-03
NO831473L (no) 1983-10-28
ATA125383A (de) 1986-05-15
GB2133401A (en) 1984-07-25
PT76595A (fr) 1983-05-01
SE8302347D0 (sv) 1983-04-26
IL68497A0 (en) 1983-07-31

Similar Documents

Publication Publication Date Title
NO942415L (no) Fremgangsmåte for fremstilling av behandling av surgass og hydrokarbonvæskeströmmer
CA2126305A1 (en) New treatments using venlafaxine
GB857576A (en) Substituted biguanides
DK0479384T3 (da) Fremgangsmåde til behandling af dinitroaniliner med sulfit til reduktion af urenheder og til reduktion af evne til at danne nitrosaminer
DE3376190D1 (de) N-azidophenylsulfonyl-n'-pyrimidinyl- and -triazinyl urea
ES2062489T3 (es) Procedimiento para obtencion de isotiocianatos.
DK229480A (da) Fremgangsmaade til fremstilling af guanidinderivater deres tautomere forbindelser og salte
KR870007108A (ko) 벤조일우레아 화합물의 제조방법
JPS5592348A (en) Preparation of 1,17-diamino-9-azaheptadecane
PT73527B (en) Process for the preparation of n-sulphenylated ureas having fungicidal effect
JPS5321857A (en) Method of treating ammonia-containing liquid
ATE20349T1 (de) Heterocyclisch substituierte nitrile, ihre herstellung und verwendung als arzneimittel.
DE69402092D1 (de) Herstellung des Natriumsalzes von 1-Amino-1-Cyanamido-2,2-Dicyanoethylen
FR1233866A (fr) Procédé de préparation de mono- et polyisocyanates inoffensifs au point de vue physiologique, avec une faible pression de vapeur
DE3773595D1 (en) Furan- und thiophencarbonsaeurepropargylester.
JPS5430156A (en) Synthesis of benzamide derivative
IE780577L (en) Propanolamines
JPS5242829A (en) Process for preparation of aminophenol and phenylenediamine
JPS5283533A (en) 6-substituted naphtehalene-2-oxyalkylamines
SU503934A1 (ru) Дисперсионно-твердеющий элинвар
MX3243E (es) Procedimiento para preparar 2 , 6 - di nitro anilinas 3 - substituidas
GB1483684A (en) Benzothiazole derivatives
GB1086527A (en) Urea derivatives and mixtures containing them
GB989559A (en) Polyamines
KR830010205A (ko) 고장력 후강판의 제조방법

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment